Coumarin derivatives have been recognized for their antithrombotic, anti-inflammatory, and antioxidant properties, and daphnetin is one of the natural coumarin derivatives isolated from Nakai. Although the pharmacological value of daphnetin is well documented in diverse biological activities, its antithrombotic effect has not been studied to date. Here, we characterized the role and underlying mechanism of daphnetin in the regulation of platelet activation using murine platelets. In order to check the effect of daphnetin on platelet function, we first measured the effect of daphnetin on platelet aggregation and secretion. Collagen-induced platelet aggregation and dense granule secretion were partially inhibited by daphnetin. Interestingly, 2-MeSADP-induced secondary waves of aggregation and secretion were completely inhibited by daphnetin. It is known that 2-MeSADP-induced secretion and the resultant secondary wave of aggregation are mediated by the positive feedback effect of thromboxane A (TxA) generation, suggesting the important role of daphnetin on TxA generation in platelets. Consistently, daphnetin did not affect the 2-MeSADP-induced platelet aggregation in aspirinated platelets where the contribution of TxA generation was blocked. Additionally, platelet aggregation and secretion induced by a low concentration of thrombin, which is affected by the positive feedback effect of TxA generation, were partially inhibited in the presence of daphnetin. Importantly, 2-MeSADP- and thrombin-induced TxA generation was significantly inhibited in the presence of daphnetin, confirming the role of daphnetin on TxA generation. Finally, daphnetin significantly inhibited 2-MeSADP-induced cytosolic phospholipase A (cPLA) and ERK phosphorylation in non-aspirinated platelets. Only cPLA phosphorylation, not ERK phosphorylation, was significantly inhibited by daphnetin in aspirinated platelets. In conclusion, daphnetin plays a critical role in platelet function by inhibiting TxA generation through the regulation of cPLA phosphorylation.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10055769PMC
http://dx.doi.org/10.3390/ijms24065779DOI Listing

Publication Analysis

Top Keywords

txa generation
28
platelet aggregation
16
daphnetin
15
aggregation secretion
12
inhibited daphnetin
12
generation
8
coumarin derivatives
8
daphnetin platelet
8
platelet function
8
partially inhibited
8

Similar Publications

Lower gastrointestinal bleeding (LGIB) is a challenging and potentially life-threatening medical condition that often necessitates prompt intervention. In the quest to improve patient outcomes, one therapeutic agent has garnered significant attention - tranexamic acid (TXA). The basic aim of the study is to systematically review the role of TXA in LGIB.

View Article and Find Full Text PDF

Introduction: Tranexamic acid (TXA) is an antifibrinolytic drug commonly used in total knee arthroplasty (TKA). Intravenous (IV) and topical TXA therapy have been extensively studied and shown to reduce blood loss, length of hospital stay, and blood transfusion rates following TKA. Despite the extensive literature regarding IV and topical TXA in orthopedics, there is a current dearth of studies analyzing oral usage.

View Article and Find Full Text PDF

Does Intravenous Tranexamic Acid Reduce Blood Loss at the Time of Total Colpocleisis? A Randomized Double-Blind Placebo-Controlled Trial.

J Minim Invasive Gynecol

January 2025

Division of Urogynecology, Department of Obstetrics and Gynaecology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada; Present Affiliation (not associated with study): Department of Obstetrics and Gynecology, Cambridge Memorial Hospital, Cambridge, Ontario, Canada.

Objective: To determine the efficacy of intravenous (IV) tranexamic acid (TXA) in reducing blood loss and blood transfusion among women undergoing total colpocleisis.

Design: Double-blind, randomized, placebo-controlled trial.

Setting: Tertiary academic urogynecology practice.

View Article and Find Full Text PDF

Importance: Perioperative bleeding is common in general surgery. The POISE-3 (Perioperative Ischemic Evaluation-3) trial demonstrated efficacy of prophylactic tranexamic acid (TXA) compared with placebo in preventing major bleeding without increasing vascular outcomes in noncardiac surgery.

Objective: To determine the safety and efficacy of prophylactic TXA, specifically in general surgery.

View Article and Find Full Text PDF

Reduction mammaplasty is a common, elective, and safe operation, usually executed in healthy patients. Nonetheless, postoperative complications like bleeding and seroma formation can occur and significantly complicate the postoperative course. Tranexamic acid (TXA), a commonly used antifibrinolytic drug, offers a novel approach to reduce these complications.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!